The Fosun Pharmaceutical Group (Fosun Pharma), based in Shanghai and a leading healthcare company in China, has announced the acquisition of 95.6% of the shares of Alma Lasers Ltd. whose R&D Centre is located in Caesarea Israel. The acquisition is being made together with Pramerica-Fosun Fund and its cost will not exceed US$240 million.
This is FosunPharma’s first international M&A transaction since a prior share offering in Hong Kong in 2012 brought it to international capital markets. Fosun Pharma is a member of the Fosun International (Fosun), a Chinese industrial conglomerate also listed on the Hong Kong Stock Exchange. Fosun has an insurance joint venture with the US Prudential Insurance Company and they together they have also co-founded the private equity firm Pramerica-Fosun Fund which is one of the investors in the Alma transaction.
Alma Lasers (Alma) is an internationally well-known manufacturer of laser, light-based, radio frequency and ultrasound products with an integrated product portfolio for aesthetic and medical applications. With its world-leading core research and development (R&D) capabilities in the medical and aesthetic device manufacturing field, Alma Lasers has established a leading global brand with sales of over $100 million annually and plants and offices worldwide. Alma today is reported to hold a 15% share of the global market for high-end aesthetic laser devices.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
There are three key sectors in the laser medical and aesthetic device industry; high-end aesthetic devices, surgical devices and smaller devices for domestic use in the home. Alma Lasers is already one of the leaders in the high-end aesthetic device market and has now begun to gain a foothold in the surgical device market during 2012. At the same time, Alma Lasers is completing the R&D stage for new devices fit plans to introduce for domestic use.
Doctor Ziv Karni, the Chief Executive Officer of Alma, is fully confident with this cooperation with Fosun Pharma, saying, “The Alma team is glad to become one of the members of Fosun Pharma. Fosun Pharma’s previous successful experience in medical healthcare as well as the medical aesthetic device fields, will become an point of focus for Alma’s own excellent platform in Asian and worldwide markets. We look forward to cooperating with Fosun Pharma’s management team and benefit from their professional experience.”
Globally, there is still room for growth in the aesthetic medical equipment market. Alma Lasers began doing business in China in 2003, and has already become the market leader in the field of medical cosmetic lasers. China is one of the biggest markets for Alma Lasers.
Mr. Chen Qiyu, Chairman of Fosun Pharma, said, “We are confident in the growth of the global aesthetics industry, especially in China, Brazil, Russia and India. There is still a huge development opportunity in developing countries. We will continue to support the global business development of Alma Lasers.”
About Alma Lasers Ltd.
Founded in 1999, Alma Lasers is a renowned global manufacturer of laser, light-based, radiofrequency and ultrasound devices foraesthetic and medical applications, with a fully integrated product supply chain. The company’s R&D headquarters is situated in Caesarea, Israel and its global support center is located in Chicago, USA.
Dr. Ziv Karni, the founder of Alma Lasers, is the CEO of the company. Dr. Karni has been working in the R&D of medical lasers for more than 20 years and is the patent explorer and owner of a number of medical laser technologies. Dr. Karni is one of the pioneers in introducing lasers into the medical field and promoting the integration of laser technology and clinical application. As of the end of 2012, the near 40-strong R&D team that he leads has 74 patents, and applications for an additional 23 patents.
Fosun Pharma is a leading healthcare company in China. The Group was established in 1994 with headquarters located in Shanghai, and was listed on the Shanghai Stock Exchange in 1998.
